Immunogenic properties of amyloid beta oligomers

Journal of Biomedical Science

Volumn 20, Issue 1, 2013, Pages

  Dalgediene, Indre ^a   Lasickiene, Rita ^a   Budvytyte, Rima ^a   Valincius, Gintaras ^a   Morkuniene, Ramune ^b   Borutaite, Vilmante ^b   Zvirbliene, Aurelija ^a  

^a VILNIUS UNIVERSITY   (Lithuania)

^b LITHUANIAN UNIVERSITY OF HEALTH SCIENCES   (Lithuania)

Author keywords

Alzheimer's disease (AD); Amyloid beta (A ); Epitope mapping; Immunogenicity; Neurotoxic oligomers; Neurotoxicity

Indexed keywords

AMYLOID BETA 1-42 OLIGOMER; AMYLOID BETA PROTEIN; EPITOPE; IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY; OLIGOMER; POLYCLONAL ANTIBODY; UNCLASSIFIED DRUG; ALZHEIMER DISEASE VACCINE; AMYLOID BETA PROTEIN (1 42); AMYLOID BETA-PROTEIN (1-42); ANTIGEN; PEPTIDE FRAGMENT;

AMINO TERMINAL SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; B LYMPHOCYTE ACTIVATION; CONTROLLED STUDY; EPITOPE MAPPING; FEMALE; HELPER CELL; IMMUNE RESPONSE; IMMUNOGENICITY; IN VITRO STUDY; MOUSE; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; ALZHEIMER DISEASE; ANIMAL; B LYMPHOCYTE; DISEASE MODEL; DRUG EFFECT; IMMUNOLOGY; IMMUNOTHERAPY; INNATE IMMUNITY; METABOLISM; RAT;

MUS; RATTUS;

ALZHEIMER DISEASE; ALZHEIMER VACCINES; AMYLOID BETA-PEPTIDES; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS; B-LYMPHOCYTES; DISEASE MODELS, ANIMAL; EPITOPE MAPPING; IMMUNITY, INNATE; IMMUNOTHERAPY; MICE; PEPTIDE FRAGMENTS; RATS;

EID: 84874042646     PISSN: 10217770     EISSN: 14230127     Source Type: Journal    
DOI: 10.1186/1423-0127-20-10     Document Type: Article

References (20)

1. Regulation of cholesterol and sphingomyelin metabolism by amyloid-beta and presenilin. Grimm MO, Grimm HS, Pätzold AJ, Zinser EG, Halonen R, Duering M, Tschäpe JA, De Strooper B, Müller U, Shen J, Hartmann T, Nat Cell Biol 2005 7 11 1118 1123 10.1038/ncb1313 16227967
2. Size-dependent neurotoxicity of beta-amyloid oligomers. Cizas P, Budvytyte R, Morkuniene R, Moldovan R, Broccio M, Lösche M, Niaura G, Valincius G, Borutaite V, Arch Biochem Biophys 2010 496 2 84 92 10.1016/j.abb.2010.02.001 20153288
3. Potential neurotoxic inflammatory responses to Abeta vaccination in humans. Münch G, Robinson SR, J Neural Transm 2002 109 7-8 1081 1087 12111445 (Pubitemid 34762346)
4. Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial. Gilman S, Koller M, Black RS, Jenkins L, Griffith SG, Fox NC, Eisner L, Kirby L, Rovira MB, Forette F, Orgogozo JM, AN1792(QS-21)-201 Study Team, Neurology 2005 64 9 1553 1562 10.1212/01.WNL.0000159740.16984.3C 15883316 (Pubitemid 40617691)
5. Long-term effects of Abeta42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial. Holmes C, Boche D, Wilkinson D, Yadegarfar G, Hopkins V, Bayer A, Jones RW, Bullock R, Love S, Neal JW, Zotova E, Nicoll JA, Lancet 2008 372 9634 216 223 10.1016/S0140-6736(08) 61075-2 18640458 (Pubitemid 351978111)
6. Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Kayed R, Head E, Thompson JL, McIntire TM, Milton SC, Cotman CW, Glabe CG, Science 2003 300 5618 486 489 10.1126/science.1079469 12702875 (Pubitemid 36444329)
7. Soluble amyloid beta-oligomers affect dielectric membrane properties by bilayer insertion and domain formation: implications for cell toxicity. Valincius G, Heinrich F, Budvytyte R, Vanderah DJ, McGillivray DJ, Sokolov Y, Hall JE, Lösche M, Biophys J 2008 95 10 4845 4861 10.1529/biophysj.108. 130997 18515395
8. Generation of monoclonal antibodies of desired specificity using chimeric polyomavirus-derived virus-like particles. Zvirbliene A, Samonskyte L, Gedvilaite A, Voronkova T, Ulrich R, Sasnauskas K, J Immunol Methods 2006 311 1-2 57 70 16516908 (Pubitemid 44389478)
9. Generation of recombinant metapneumovirus nucleocapsid protein as nucleocapsid-like particles and development of virus-specific monoclonal antibodies. Petraityte-Burneikiene R, Nalivaiko K, Lasickiene R, Firantiene R, Emužyte R, Sasnauskas K, Žvirbliene A, Virus Res 2011 161 2 131 139 10.1016/j.virusres.2011.07.009 21827798
10. Continuous cultures of fused cells secreting antibody of predefined specificity. Köhler G, Milstein C, Nature 1975 256 5517 495 497 10.1038/256495a0 1172191
11. Naturally occurring autoantibodies against beta-amyloid: investigating their role in transgenic animal and in vitro models of Alzheimer's disease. Dodel R, Balakrishnan K, Keyvani K, Deuster O, Neff F, Andrei-Selmer LC, Röskam S, Stüer C, Al-Abed Y, Noelker C, Balzer-Geldsetzer M, Oertel W, Du Y, Bacher M, J Neurosci 2011 31 15 5847 5854 10.1523/JNEUROSCI.4401-10. 2011 21490226
12. Prevention of amyloid-beta oligomer-induced neuronal death by EGTA, estradiol, and endocytosis inhibitor. Cižas P, Jekabsone A, Borutaite V, Morkūniene R, Medicina 2011 47 2 107 112 21734444
13. A structural model for Alzheimer's beta -amyloid fibrils based on experimental constraints from solid state NMR. Petkova AT, Ishii Y, Balbach JJ, Antzutkin ON, Leapman RD, Delaglio F, Tycko R, Proc Natl Acad Sci U S A 2002 99 26 16742 16747 10.1073/pnas.262663499 12481027 (Pubitemid 36034043)
14. Self-propagating, molecular-level polymorphism in Alzheimer's beta-amyloid fibrils. Petkova AT, Leapman RD, Guo Z, Yau WM, Mattson MP, Tycko R, Science 2005 307 5707 262 265 10.1126/science.1105850 15653506 (Pubitemid 40116242)
15. Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease. DeMattos RB, Bales KR, Cummins DJ, Dodart JC, Paul SM, Holtzman DM, Proc Natl Acad Sci U S A 2001 98 15 8850 8855 10.1073/pnas.151261398 11438712 (Pubitemid 32678116)
16. Targeting beta-amyloid pathology in Alzheimer's disease with Abeta immunotherapy. Nitsch RM, Hock C, Neurotherapeutics 2008 5 3 415 420 10.1016/j.nurt.2008.05.013 18625453 (Pubitemid 351952496)
17. Abeta42 immunization in Alzheimer's disease generates Abeta N-terminal antibodies. Lee M, Bard F, Johnson-Wood K, Lee C, Hu K, Griffith SG, Black RS, Schenk D, Seubert P, Ann Neurol 2005 58 3 430 435 10.1002/ana.20592 16130106 (Pubitemid 41266629)
18. Intravenous immunoglobulins containing antibodies against beta-amyloid for the treatment of Alzheimer's disease. Dodel RC, Du Y, Depboylu C, Hampel H, Frölich L, Haag A, Hemmeter U, Paulsen S, Teipel SJ, Brettschneider S, Spottke A, Nölker C, Möller HJ, Wei X, Farlow M, Sommer N, Oertel WH, J Neurol Neurosurg Psychiatry 2004 75 10 1472 1474 10.1136/jnnp.2003.033399 15377700 (Pubitemid 39279821)
19. Peripheral and central biodistribution of (111)In-labeled anti-beta-amyloid autoantibodies in a transgenic mouse model of Alzheimer's disease. Bacher M, Depboylu C, Du Y, Noelker C, Oertel WH, Behr T, Henriksen G, Behe M, Dodel R, Neurosci Lett 2009 449 3 240 245 10.1016/j.neulet.2008.08.083 18786612
20. 18-Month study of intravenous immunoglobulin for treatment of mild Alzheimer disease. Relkin NR, Szabo P, Adamiak B, Burgut T, Monthe C, Lent RW, Younkin S, Younkin L, Schiff R, Weksler ME, Neurobiol Aging 2009 30 11 1728 1736 10.1016/j.neurobiolaging.2007.12.021 18294736